Premium
Adverse metabolic and cardiovascular risk following treatment of acute lymphoblastic leukaemia in childhood; two case reports and a literature review
Author(s) -
Amin P.,
Shah S.,
Walker D.,
Page S. R.
Publication year - 2001
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1046/j.1464-5491.2001.00591.x
Subject(s) - medicine , diabetes mellitus , total body irradiation , pediatrics , acute lymphocytic leukemia , proteinuria , malignancy , chemotherapy , lymphoblastic leukemia , cyclophosphamide , leukemia , endocrinology , kidney
We report two patients who survived childhood acute lymphoblastic leukaemia (ALL) following treatment with chemotherapy, total body irradiation (TBI) and bone marrow transplantation (BMT). The first case presented with an acute cerebral infarction at 23 years of age and was found to have non‐ketotic diabetes and gross mixed hyperlipidaemia; the second presented with non‐ketotic diabetes, hypertension, proteinuria and dyslipidaemia at age 16 years. The association of glucose intolerance with other vascular risk factors in young adult survivors of BMT was recently highlighted in a follow‐up study of 23 survivors of BMT [1], but none presented with such gross mixed hyperlipidaemia. The improving survival rates of childhood malignancy over the last two decades will present adult physicians with patients who have accelerated vascular risk at a young age who will require early treatment to modify it. Diabet. Med. 18, 849–853 (2001)